BRIEF published on 01/29/2026 at 12:25, 9 months 12 days ago Eckert & Ziegler annonce de solides performances financières en 2025 Résultats Financiers Croissance Des Ventes Revenu Net Augmentation Du Résultat D'exploitation Performances 2025
BRIEF published on 01/29/2026 at 12:25, 9 months 12 days ago Eckert & Ziegler Reports Strong Financial Performance in 2025 Financial Results Net Income Sales Growth EBIT Increase 2025 Performance
PRESS RELEASE published on 01/29/2026 at 12:20, 9 months 12 days ago Eckert & Ziegler on Track as Planned and Achieves Another Record Year in 2025 Eckert & Ziegler reports record sales and profits in 2025, with sales reaching approx. €312 million and net income approx. €48 million. Company is a leader in nuclear medicine Financial Results Eckert & Ziegler Record Year 2025 Nuclear Medicine
BRIEF published on 01/12/2026 at 15:01, 9 months 29 days ago Eckert & Ziegler participeront à la conférence JP Morgan Healthcare Conférence Sur Les Soins De Santé JP Morgan Eckert Et Ziegler Composants Isotopiques Radiopharmaceutique
BRIEF published on 01/12/2026 at 15:01, 9 months 29 days ago Eckert & Ziegler to Attend J.P. Morgan Healthcare Conference Eckert & Ziegler Healthcare Conference J.P. Morgan Radiopharmaceutical Isotope Components
PRESS RELEASE published on 01/12/2026 at 14:56, 9 months 29 days ago Eckert & Ziegler to Participate in the 44th Annual J.P. Morgan Healthcare Conference Eckert & Ziegler SE to participate in the 44th Annual J.P. Morgan Healthcare Conference. Dr. Harald Hasselmann, CEO, will present on 14 January 2026 in San Francisco, CA Healthcare Conference Eckert & Ziegler SE J.P. Morgan Healthcare Conference Dr. Harald Hasselmann
BRIEF published on 01/08/2026 at 09:05, 10 months 2 days ago Eckert & Ziegler: A Strong Case for Investment Amidst Market Volatility Investment Growth Radiopharmaceuticals Stock Performance Radioisotopes
BRIEF published on 01/08/2026 at 09:05, 10 months 2 days ago Eckert et Ziegler : Un argument convaincant en faveur de l’investissement malgré la volatilité des marchés Croissance Investissement Produits Radiopharmaceutiques Performance Boursière Radio-isotopes
PRESS RELEASE published on 01/08/2026 at 09:00, 10 months 2 days ago Original-Research: Eckert & Ziegler SE (von NuWays AG): BUY Initiation research by NuWays AG recommends buying Eckert & Ziegler SE (DE0005659700) with a target price of EUR 23, citing growth in targeted radiopharmaceuticals market and unique business positioning Buy Recommendation Target Price Eckert & Ziegler SE Radiopharmaceuticals Initiation Research
BRIEF published on 12/05/2025 at 16:15, 11 months 5 days ago Executive Board Restructuring at Eckert & Ziegler Executive Board Eckert & Ziegler Restructuring Nuclear Medicine Isotope Products
Published on 11/11/2026 at 03:30, 4 hours 50 minutes ago CoTec Holdings Corp. Files Third Quarter Financial Statements and MD&A and Provides Market Commentary
Published on 11/11/2026 at 00:40, 7 hours 40 minutes ago Upgraded Tunkillia MRE Validates Optimised Scoping Study
Published on 11/10/2026 at 23:30, 8 hours 50 minutes ago CCL Industries Announces 2026 Third Quarter Results
Published on 11/10/2026 at 23:00, 9 hours 20 minutes ago Vanta Announces Appointment of Chief Financial Officer and Corporate Secretary
Published on 11/10/2026 at 23:00, 9 hours 20 minutes ago Battery X Metals Announces Appointment of Chief Financial Officer and Corporate Secretary
Published on 11/11/2026 at 08:14, 6 minutes ago LAIQON sets the course for its next phase of growth with a joint CEO structure
Published on 11/11/2026 at 08:05, 15 minutes ago BLACKYAK Wins Grand Prix at ISPO Amsterdam 2026, A Testament to Its Mountain-Driven Innovation
Published on 11/11/2026 at 08:05, 15 minutes ago Richmond Hill Resources PLC: Sakoose Drilling Underway - First Hole Completed
Published on 11/11/2026 at 08:00, 20 minutes ago Einhell grows in the first nine months of 2026 and strengthens its financial position
Published on 11/10/2026 at 18:00, 14 hours 20 minutes ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 14 hours 35 minutes ago Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:35, 14 hours 45 minutes ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 14 hours 48 minutes ago CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.
